Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment
NCT ID: NCT02936947
Last Updated: 2022-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
8 participants
INTERVENTIONAL
2016-07-31
2021-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of 2 Different Techniques for Suppression of Respiratory Motion in Lung Cancer Treatment With Proton Therapy Using Magnetic Resonance Imaging (MRI)
NCT03669341
Mechanically-Assisted and Non-Invasive Ventilation for Breathing-related Tumor Motion Mitigation.
NCT04457102
Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
NCT03422302
Exploratory Study on Therapy for Breath Hold in Radiotherapy
NCT03729661
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
NCT05302817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Demonstrate the clinical benefit of the HFPV coupled to thoracic radiotherapy in 2 distinct and frequent clinical situations :
1. Tomotherapy for lung and left breast tumors. The investigators assume that the volume of irradiated healthy tissue will be much less when using HFPV as compared to free breathing during tomotherapy sessions .
2. In comparison with Active Breathing Control (ABC system). The investigators assume that the HFPV will lead to breathing motions cessation the same way as the ABC system, but will abrogate pause times when administrating the radiotherapy. This will shorten the radiotherapy sessions for lung patients treated with stereotaxis and for breast cancer patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tomotherapy (HFPV vs free breathing)
Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
High Frequency Percussive Ventilation
High Frequency Percussive Ventilation
Free breathing
Free breathing
linear accelerator (HFPV vs ABC)
Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.
High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC).
High Frequency Percussive Ventilation
High Frequency Percussive Ventilation
Active Breathing Control
Active Breathing Control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High Frequency Percussive Ventilation
High Frequency Percussive Ventilation
Free breathing
Free breathing
Active Breathing Control
Active Breathing Control
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* lung cancer eligible for curative tomotherapy and with a significant breathing movements amplitude
* lung cancer eligible for ablative stereotaxis
* WHO 0 or 1
Exclusion Criteria
* pulmonary functions altered
* cardiac insufficiency
* patient not able to breathe with the High Frequency Ventilation System
* risk of pneumothorax when experiencing High Frequency Ventilation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Vaudois
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean Bourhis
Head of radio-oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Bourhis, Prof
Role: PRINCIPAL_INVESTIGATOR
CHUV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire Vaudois
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUV-DO-PART-2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.